

Linus Backert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3048861/publications.pdf>

Version: 2024-02-01

16
papers

1,399
citations

840776

11
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

2329
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. <i>Lancet, The</i> , 2017, 390, 1511-1520.	13.7	350
2	Immunoinformatics and epitope prediction in the age of genomic medicine. <i>Genome Medicine</i> , 2015, 7, 119.	8.2	178
3	The immunopeptidomic landscape of ovarian carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9942-E9951.	7.1	152
4	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E166-75.	7.1	150
5	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
6	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <i>Blood</i> , 2015, 126, 1203-1213.	1.4	103
7	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. <i>Journal of Immunology</i> , 2017, 199, 2639-2651.	0.8	81
8	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. <i>Cancer Research</i> , 2018, 78, 4627-4641.	0.9	56
9	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1316438.	4.6	42
10	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
11	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , 2018, 135, 923-938.	7.7	36
12	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32.	8.2	32
13	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. <i>PLoS ONE</i> , 2016, 11, e0167017.	2.5	17
14	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and -pan-leukemia-antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	1.8	12
15	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. <i>Leukemia and Lymphoma</i> , 2018, 59, 1949-1958.	1.3	4
16	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. <i>Blood</i> , 2015, 126, 1722-1722.	1.4	0